This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Companion Diagnostics Market, 2012-2023

2. INTRODUCTION2.1. Traditional Medicine and Diagnostics: The One for All Concept2.2. Milestone in Biotechnology: Decoding of Human Genetic Code in 20032.3. Changing Face of Medicine: Personalised Medicine and Diagnostics2.3.1. Personalised Medicine vs. Traditional Medicine2.3.2. Personalised Medicine Diagnostics2.3.3. Personalised Medicine Diagnostics and Pharmacogenomic Biomarkers2.3.3.1. Development of Biomarkers Into Companion Diagnostics2.3.3.2. The Three Entry Points for a Companion Diagnostic to Associate with a Drug2.3.3.3. Low Translation Rates of Biomarkers to Companion Diagnostics2.4. Companion Diagnostic: Definition2.4.1. Types of Companion Diagnostics2.4.2. Advantages of Companion Diagnostics

3. COMPANION DRUGS MARKET, 20123.1. Chapter Overview3.2. 41.2% of the New Molecular Entities were Approved with a Pharmacogenomic Biomarker by the FDA3.3. Companion Drugs in the Market3.3.1. Companion Drugs in the Market have Achieved Blockbuster Status as Well3.3.2. Oncology was the Leading Indication Targeted by Companion Drugs3.3.2.1. Roche Laboratories had the Most Number of Successful Companion Diagnostics3.4. Case Studies3.4.1. Trastuzumab (Herceptin): A Successful Example of Personalised Medicine3.4.2. Crizotinib (Xalkori): From Conception to Market in Four Years3.4.3. Vemurafenib (Zelboraf): Co-development with Companion Diagnostic Accelerating the Time to Market3.5. Gefitinib (Iressa): Revival with Companion Diagnostic

4. COMPANION DIAGNOSTICS MARKET, 2012-20234.1. Chapter Overview4.2. Personalised Medicine Diagnostics as a Subset of In Vitro Diagnostics4.2.1. Personalised Medicine Diagnostics Market, 20124.3. Companion Diagnostics Represented 10.1% of the Personalised Medicine Diagnostics Market in 20124.4. Companion Diagnostics Market, 20124.5. Companion Diagnostics Market, 2013-20234.6. Molecular and Tissue Diagnostics Market, 20124.6.1. Molecular and Tissue Diagnostics Market, 2013-20184.7. Marketed Companion Diagnostics, 20124.7.1. Preference of LDTs Over Kits4.8. Companion Diagnostics in Pipeline: Story of New Entrants4.8.1. Oncology Dominates the Pipeline as Well4.8.2. Collaboration of Drug-Diagnostic Developers is the Most Common Model4.8.3. Start-Ups Gaining Attention

5. REGIONAL MARKETS FOR COMPANION DIAGNOSTICS, 2012-20235.1. Chapter Overview5.2. Companion Diagnostics Market: Regional Outlook5.3. The US Market For Companion Diagnostics, 20125.3.1. Current FDA Classification of IVD Tests5.3.2. Companion Diagnostic Testing5.3.3. FDA Promoting the Development of Companion Diagnostics5.4. The European Market for Companion Diagnostics, 20125.4.1. Regulation of IVDs in Europe: Current State5.4.2. Proposed Change in Classification to Alter the Regulation of Companion Diagnostics5.4.3. Companion Diagnostics Market in Europe (EU5), 20125.4.3.1. Germany5.4.3.1.1. Companion Diagnostic Testing5.4.3.1.2. Investments in Personalised Healthcare5.4.3.2. France5.4.3.2.1. Diagnostic Testing in France5.4.3.2.2. Companion Diagnostic Testing5.4.3.2.3. Challenges in the French Companion Diagnostics Market5.4.3.2.4. Investments for Future Personalised Diagnostics5.4.3.3. UK5.4.3.3.1. Diagnostic Testing in the UK5.4.3.3.2. State of HER2, KRAS and EGFR Testing5.4.3.4. Investments for Future Personalised Diagnostics5.4.3.5. Italy5.4.3.6. Spain5.5. The Japanese Market For Companion Diagnostics, 20125.5.1. Companion Diagnostics Testing5.5.2. Driving Factors for Growth5.6. Rest of the World Companion Diagnostics Market, 20125.6.1. Companion Diagnostic Testing in China: Tests and Companies5.7. Regional Markets for Companion Diagnostics, 2012-2023

6. PROFILES OF LEADING COMPANIES6.1. Abbott Molecular6.1.1. Marketed and Pipeline Companion Diagnostics6.1.2. Financial Performance6.2. Qiagen6.2.1. Expanding Through Acquisitions6.2.2. Marketed and Pipeline Products6.2.3. Financial Performance6.2.4. Recent Developments6.3. Dako (a Subsidiary of Agilent Technologies)6.3.1. Marketed and Pipeline Products6.3.2. Financial Performance6.3.3. Recent Developments6.4. Roche Laboratories: Theranostics' Market Giant6.4.1. Marketed and Pipeline Products6.4.1.1. Marketed Products6.4.1.2. Products In the Pipeline6.4.1.3. Preferred Partner for Companion Diagnostics6.4.2. Financial Performance

3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs